Evotec SE
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Dec 31, 2025 | Apr 8, 2026 | During market hours | $253.30M | – | – |
Company guidance
Outlook given with results on Apr 8, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted Group EBITDAnon-GAAP | 2026 | 0 to 40 | – |
| Group revenuesGAAP | 2026 | 700 to 780 | – |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Evotec filed with the SEC
Manfred Eigen Campus / Essener Bogen 7
EX-99.2 to Form 6-K
Disclosure of an inside information
EX-99.1 to Form 6-K
Announces Chief Scientific Officer Transition
EX-99.1 to Form 6-K
First-in-human Phase 1 study initiated for investigational
EX-99.1 to Form 6-K
For further information, please contact : Dr. Sarah
EX-99.1 to Form 6-K
Disclosure of an inside information
EX-99.1 to Form 6-K
Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
EX-99.2 to Form 6-K
X Notification of Major Holdings
EX-99.1 to Form 6-K
Directors’ Dealings | 16 June 2026 17:46
EX-99.1 to Form 6-K
For further information, please contact : Dr. Sarah
EX-99.1 to Form 6-K
Evotec Announces New Nomination to Board of Directors
EX-99.1 to Form 6-K
Evotec Announces Chief Financial Officer Transition
EX-99.1 to Form 6-K
Nominates Dieter Weinand as Supervisory Board Chairman
EX-99.1 to Form 6-K
Evotec to Receive Approx. $100 Million as Part of Tubulis Acquisition
EX-99.2 to Form 6-K
X Notification of Major Holdings
EX-99.1 to Form 6-K
X Notification of Major Holdings
EX-99.2 to Form 6-K
Manfred Eigen Campus / Essener Bogen 7
EX-99.3 to Form 6-K
Manfred Eigen Campus / Essener Bogen 7
EX-99.1 to Form 6-K
X Notification of Major Holdings
EX-99.2 to Form 6-K
Just – Evotec Biologics Receives
EX-99.1 to Form 6-K
X Notification of Major Holdings
EX-99.2 to Form 6-K
X Notification of Major Holdings
EX-99.1 to Form 6-K
X Notification of Major Holdings
EX-99.2 to Form 6-K
X Notification of Major Holdings
EX-99.1 to Form 6-K
X Notification of Major Holdings
EX-99.2 to Form 6-K
Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations
EX-99.1 to Form 6-K
Evotec closes sale of Just
EX-99.1 to Form 6-K
Announcement pursuant to Article 5(1)(a) of
EX-99.1 to Form 6-K
IN REVENUE MIX ALIGNED WITH NEW STRATEGY FOR LONG-TERM PROFITABLE GROWTH
EX-99.1 to Form 6-K
In a landmark industry transaction, Evotec
EX-99.1 to Form 6-K
REVENUE MIX ALIGNED WITH NEW STRATEGY FOR SUSTAINABLE PROFITABLE GROWTH
EX-99.1 to Form 6-K
Disclosure of an inside information
EX-99.1 to Form 6-K
Disclosure of an inside information acc. to Article 17 MAR of the
EX-99.1 to Form 6-K
Evotec adjusts revenue guidance and confirms
EX-99.2 to Form 6-K